

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 February 2022 (24.02.2022)



(10) International Publication Number
WO 2022/040482 A1

- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
C07K 16/30 (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/US2021/046789
- (22) **International Filing Date:**
19 August 2021 (19.08.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/067,834 19 August 2020 (19.08.2020) US
63/092,272 15 October 2020 (15.10.2020) US
- (71) **Applicant:** XENCOR, INC. [US/US]; 111 West Lemon Avenue, Monrovia, CA 91016 (US).
- (72) **Inventors:** DESJARLAIS, John, R.; c/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US).
MOORE, Gregory; c/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US).
- (74) **Agent:** NGUYEN, Louis-Vu, T. et al.; Morgan, Lewis & Bockius, LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) **Title:** ANTI-CD28 AND/OR ANTI-B7H3 COMPOSITIONS

Figure 1

Human CD28 sequence SEQ ID NO:757
>sp|P10747|CD28_HUMAN T-cell-specific surface glycoprotein CD28 OS=Homo sapiens OX=9606 GN=CD28 PE=1 SV=1
MLRLLLALNLFPSIQVTGNKILVKQSPMLVAYDNAVNLSCKYSYNLFSREFRASLHKGLDSAVEVCVVGNYSSQQLQ
VYSKTGFNC DGKLGNESVTIFYLQNLVYNQTDIYFCKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFLPGPSKPFW
VLVVGGVGLACYSLLVTVAFIIPWVRSKSRLLHSDYMMNTPRRPGPTRKHYPYAPPRDFAAYRS

Human CD28, extracellular domain SEQ ID NO:758
>sp|P10747|19-152
NKILVKQSPMLVAYDNAVNLSCKYSYNLFSREFRASLHKGLDSAVEVCVVGNYSSQQLQVYSKTGFNC DGKLGNESV
TFYLQNLVYNQTDIYFCKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFLPGPSKPF

Mouse CD28 sequence SEQ ID NO:759
>sp|P31041|CD28_MOUSE T-cell-specific surface glycoprotein CD28 OS=Mus musculus OX=10090 GN=Cd28 PE=1 SV=2
MTLRLLFLALNLFPSIQVTGNKILVKQSPMLVAYDNAVNLSCKYSYNLFAKEFRASLYKGVNSDVEVCVVGNGNFTYQ
QFRSNAEFC DGDNDNETVTFRLWNHVNHTDIYFCKIEVMYPPPYLDNERSNGTIIHKEKHLCHTQSSPKLFWAL
VVVAGVLECYGLLVTVLVCVITNSRRNLLQSDYMMNTPRRPGLTRKPYQPYAPARDFAAYRP

Mouse CD28, extracellular domain SEQ ID NO:760
>sp|P31041|20-150
NKILVKQSPMLVAYDNAVNLSCKYSYNLFAKEFRASLYKGVNSDVEVCVVGNGNFTYQPFQFRSNAEFC DGDNDNETV
TFRLWNHVNHTDIYFCKIEVMYPPPYLDNERSNGTIIHKEKHLCHTQSSPKL

Cynomolgus CD28 sequence SEQ ID NO:761
>tr|Q0PDN3|Q0PDN3_MACFA CD28 OS=Macaca fascicularis OX=9541 GN=CD28 PE=2 SV=1
MLRLLLALNLFPSIQVTGNKILVKQSPMLVAYDNAVNLSCKYSYNLFSREFRASLHKGLDSAVEVCVVGNYSSQQLQ
VYSKTGFNC DGKLGNESVTIFYLQNLVYNQTDIYFCKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFLPGPSKPFW
ALVVGGVGLACYSLLVTVAFIIPWVRSKSRLLHSDYMMNTPRRPGPTRKHYPYAPPRDFAAYRS

Cynomolgus CD28, extracellular domain SEQ ID NO:762
>tr|Q0PDN3|19-152
NKILVKQSPMLVAYDNAVNLSCKYSYNLFSREFRASLHKGLDSAVEVCVVGNYSSQQLQVYSKTGFNC DGKLGNESV
TFYLQNLVYNQTDIYFCKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFLPGPSKPF

(57) **Abstract:** Provided herein are novel anti-CD28 x anti-B7H3 (also referred to as "αCD28 x αB7H3") heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject αCD28 x αB7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*